Cervical cancer prevention advances with new immunotherapy findings, addressing disparities and improving outcomes for ...

A new FDA application for vepdegestrant offers hope for advanced breast cancer patients with ESR1 mutations, showcasing ...

In an interview with Targeted OncologyTM, Massimo Cristofanilli, MD, medical oncologist at the Breast Center at Weill Cornell ...

During a live event, Taewoong Choi, MD, discussed the current state of therapy for transplant-ineligible newly diagnosed ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Larotrectinib is a highly selective and central nervous system-active TRK inhibitor, approved for adult and pediatric ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

JNJ-79635322 shows favorable responses and manageable safety in BCMA/GPRC5D-naïve patients with relapsed/refractory multiple ...

A panelist discusses how four FDA-approved agents treat steroid-refractory cGVHD, including ibrutinib (65% response rate), ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

The PSMAddition trial shows 177Lu PSMA-617 significantly delays progression in mHSPC when added to hormone therapy, with a ...